We have located links that may give you full text access.
Audit can ensure the safe and effective introduction of seizure prophylaxis with magnesium sulphate in obstetric practice.
Health Bulletin 2000 September
OBJECTIVE: To audit the effectiveness and safety of intravenous magnesium sulphate therapy in severe pre-eclampsia.
DESIGN: A complete audit cycle including the first eight cases receiving therapy, an intervention with staff instruction and the re-audit of eight further consecutive cases. The issues for audit were compliance with the protocol and the achievement and maintenance of therapeutic magnesium concentrations.
SETTING: Labour room, Glasgow Royal Maternity Hospital.
SUBJECTS: Women with severe pre-eclampsia fulfilling pre-determined criteria for seizure prophylaxis with intravenous magnesium therapy.
RESULTS: Protocol violations resulted both in delays in achieving therapeutic magnesium concentrations and high magnesium concentrations in five of the eight initial cases. Following circulation of the results and staff education, the re-audit demonstrated near complete compliance with the protocol and a more consistent interval to achieving a therapeutic magnesium concentration. There were no cases of eclampsia or magnesium toxicity amongst women delivering at GRMH during the period of this audit.
CONCLUSION: This audit has demonstrated that seizure prophylaxis with intravenous magnesium sulphate can be safely and effectively introduced to the obstetric management of women with severe pre-eclampsia.
DESIGN: A complete audit cycle including the first eight cases receiving therapy, an intervention with staff instruction and the re-audit of eight further consecutive cases. The issues for audit were compliance with the protocol and the achievement and maintenance of therapeutic magnesium concentrations.
SETTING: Labour room, Glasgow Royal Maternity Hospital.
SUBJECTS: Women with severe pre-eclampsia fulfilling pre-determined criteria for seizure prophylaxis with intravenous magnesium therapy.
RESULTS: Protocol violations resulted both in delays in achieving therapeutic magnesium concentrations and high magnesium concentrations in five of the eight initial cases. Following circulation of the results and staff education, the re-audit demonstrated near complete compliance with the protocol and a more consistent interval to achieving a therapeutic magnesium concentration. There were no cases of eclampsia or magnesium toxicity amongst women delivering at GRMH during the period of this audit.
CONCLUSION: This audit has demonstrated that seizure prophylaxis with intravenous magnesium sulphate can be safely and effectively introduced to the obstetric management of women with severe pre-eclampsia.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app